ARTICLE | Clinical News
Xcytrin motexafin gadolinium: Began Phase III trial
January 16, 2001 8:00 AM UTC
Pharmacyclics Inc. (PCYC), Sunnyvale, Calif. Product: Xcytrin motexafin gadolinium Business: Cancer Therapeutic category: Adjunct Target: Tumor cells Description: Injectable radiosensitizer Indicatio...